AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Selective Genetics, Inc., San Diego, and Spinal Concepts, Inc., Austin, Texas, entered into a joint development program that will combine Selective Genetics' gene- activated matrices (GAM) with Spinal Concepts' InFixa and other interbody fusion devices.
Under the agreement, Spinal Concepts will receive a worldwide, co-exclusive license for the use of GAM with interbody devices and will market the combined product. Selective Genetics will manufacture the gene therapeutic GAM and will receive up to $12 million from Spinal Concepts in license fees, equity purchases, R&D support or milestone payments. The company will also receive a royalty on sales.